NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Aktis Oncology

Aktis Oncology

Public
Boston, MassachusettsBiotechhttps://www.aktisoncology.com

Last Round

Series B

Sep 30, 2024

Total Funding Raised

$331M

Company Overview

Aktis Oncology is a biopharmaceutical company specializing in targeted radiopharmaceuticals for the treatment of various solid tumor cancers.

Sector

Biotech

Verticals

Life Sciences, Oncology

AI Layer

Non-AI

Keywords

targeted alpha radiopharmaceuticalsradiopharmaminiprotein radioconjugatestargeted alpha therapysolid tumor treatmenttheranosticsdrug discovery platformradioconjugate therapyoncology therapeuticsclinical-stage biotechNectin-4 targetpharmaceutical partnerships

Aktis Oncology Comps

Public and private peers based on sector, stage, and business model.

Aktis Oncology comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Aktis Oncology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BSep 30, 2024
Series A ExtensionAug 25, 2022
Series AMar 18, 2021

Key People

Founding team and executive leadership

Matthew Roden

President And Chief Executive Officer, And Member Of The Board Of Directors

Executive Team

Kyle Kuvalanka

Chief Financial, Chief Financial Officer

Executive Team

Shulamit Ron-Bigger

Chief Operating Officer

Executive Team

Aktis Oncology Investors

Notable investors and investment history

Aktis Oncology investors
InvestorRounds
EcoR1 CapitalSeries B, Series A, Series A Extension
Janus Henderson GroupSeries B
MPM CapitalSeries B, Series A Extension, Series A
RA Capital ManagementSeries B
TCG CrossoverSeries A, Series B, Series A Extension
A. M. Pappas & AssociatesSeries A Extension
Mirae AssetSeries A Extension

Aktis Oncology Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Aktis Oncology Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range88
Year Founded2021
Last FundingSep 30, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.